Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials to Treat Adult Metastatic Brain Tumors

Trials 51-72 of 72

Stereotactic Radiation with Sacituzumab Govitecan and Zimberelimab for the Treatment of Patients with Metastatic Triple Negative Breast Cancer with Brain Metastases, TARGET-TNBC Trial
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Stereotactic Radiosurgery in Treating Participants with Brain Metastases and Studying Their Neurocognitive Decline
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Stereotactic Radiosurgery Dose Escalation in Treating Patients with Brain Metastases
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Fractionated Stereotactic Radiation Therapy in Treating Cancer Patients with Brain Metastases That Has Not Been Removed by Surgery
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Stereotactic Radiosurgery in Treating Patients with Brain Metastasis
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Alpelisib and Pembrolizumab for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Melanoma or Triple Negative Breast Cancer, SELENA Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients with Brain Metastases
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Radiosurgery before Surgery for the Treatment of Brain Metastases
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Comparing Stereotactic Radiosurgery Margin Treatment Approaches for the Treatment of Brain Metastases
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Status: Active
Location: 2 locations
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Status: Active
Location: See ClinicalTrials.gov
Evaluation of Ascorbate-Meglumine Therapeutic for SRS
Status: Enrolling by Invitation
Location: Duke University Medical Center, Durham, North Carolina
Combination Study of SV-BR-1-GM With Retifanlimab
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Status: Temporarily Closed to Accrual
Location: 347 locations
Bevacizumab and Atezolizumab with or without Cobimetinib in Treating Patients with Untreated Melanoma Brain Metastases
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Nivolumab with Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Brain-Directed Stereotactic Radiation Therapy with or without AGulX Gadolinium-Based Nanoparticles for the Treatment of Brain Metastases
Status: Temporarily Closed to Accrual
Location: 2 locations